Patient Selection Criteria: Identifying Appropriate Candidates for Tarlatamab

Summary for Physicians:

Clinical Factors for Tarlatamab Eligibility:

• Good candidates:
• Relapsed/refractory small cell lung cancer after prior treatments
• Adequate organ function (eg, liver, kidney)
• ECOG performance status: Typically 0-1 (able to carry out normal activities or minimal assistance needed)
• Impact of treatment history:
• Chimeric antigen receptor T-cell therapy or bispecifics: May affect eligibility due to prior immune system manipulation; consider potential cross-reactivity or previous toxicities.
• Chemotherapy: Previous treatment may influence eligibility, especially if there are complications (eg, neuropathy or compromised organ function).

Prior therapies may also alter immune system response, impacting effectiveness.